Source: Middle East Eye

‘We are still using it. It is very effective when combined with other drugs in the early stages of the disease’

– Turkish official

Official tells MEE the drug is beneficial when used to treat coronavirus patients, with many Turkish doctors seeming to agree

Turkey will continue to use a controversial anti-malarial drug, hydroxychloroquine, to treat coronavirus patients despite a study warning about its side effects and the WHO’s decision to drop it from a global study, a senior Turkish official said on Tuesday.

“We are still using it,” the official told Middle East Eye, speaking anonymously in line with government protocol.

“It is very effective when combined with other drugs in the early stages of the disease. However we don’t see the same results in the later stages when the patient needs to be put on intensive care.”

Ankara said last month that the drug, which is sold under the brand name Plaquenil, was playing a major role in reducing the rate of lung infection, or pneumonia, among Covid-19 patients.

Turkey stockpiled one million units of the drug in March before the virus reached a peak in the country, and several companies began work on producing a generic version in the country.

Health ministry statistics indicated that on 24 March, 60 percent of coronavirus cases registered were patients with pneumonia, while on 6 April that it had fallen to 19.5 percent, resulting in a decrease in death rates.

With 53.07 deaths per million, Turkey takes the 26th place in a list of countries measuring fatalities on that scale, doing considerably better than most western countries.

However, a retrospective study published by medical journal the Lancet last week on 96,032 hospitalised patients, 14,888 of whom received hydroxychloroquine, claimed that the they could not confirm a benefit using the drug. They stated that it may cause death, but could not confirm that data either.

The study said that the drug caused an increase in heartbeats, potentially creating heart complications.

The World Health Organisation, as a result of the study, announced earlier this week that there would be a temporary pause on the clinical tests conducted on the drug to review all the available data on its use.

Many Turkish medical doctors, in response, cautioned the public about the Lancet study and the WHO decision, saying that it should not throw the drug out of the treatment models.

‘I haven’t seen any of my coronavirus patients who received this drug having any heart issues’

– Bengi Baser, cardiologist

Bengi Baser, a cardiologist and medical sciences professor, told MEE that hydroxychloroquine has been used since the 1930s and there wasn’t any major health concern if used within the safe dosage.

“I haven’t seen any of my coronavirus patients who received this drug having any heart issues,” she said. “Among them there were patients who had a stent put in their hearts or had chronic heart diseases.”

Baser and others said that Turkey used the drug as an anti-viral treatment in the early stages, to disrupt the replication of the virus in the body.

“An earlier study said the drug could only harm someone if its daily dosage exceeds 500g,” she said. “We only use 400g in a day for four days.”

Bulent Polat, a heart surgeon, took to Twitter to criticise the Lancet study.

“No doubt it has serious methodological mistakes, it is a retrospective study,” he said. “Even its authors said that it cannot be taken as a directive.”

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Conversation With Dr. Brian Tyson – The Chloroquine Wars Part XLI

The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.

Read More »

Dr. Brian Tyson, USA: Hydroxychloroquine – Data, Strategies and Success Treating over 6000 Covid Patients

We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.

Read More »